Kyntra Bio
KYNB

Kyntra Bio (KYNB) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
OppenheimerInitiated CoverageOutperform$35.00Jul 7, 2026
Rodman & RenshawInitiated CoverageBuy$30.00Jun 9, 2026
HC Wainwright & Co.MaintainedBuy$43.00Sep 24, 2025
HC Wainwright & Co.MaintainedBuy$43.00 from $10.00Aug 7, 2025
HC Wainwright & Co.MaintainedBuy$10.00May 13, 2025
HC Wainwright & Co.MaintainedBuy$10.00Mar 18, 2025
HC Wainwright & Co.MaintainedBuy$10.00Feb 20, 2025
B of A SecuritiesDowngradedNeutral → Underperform$2.00 from $4.00Aug 8, 2023
Goldman SachsMaintainedSell$2.00 from $16.00Jun 27, 2023
Raymond JamesDowngradedOutperform → Market PerformJun 27, 2023
B of A SecuritiesDowngradedBuy → Neutral$4.00 from $29.00Jun 26, 2023
Raymond JamesDowngradedOutperform → Market PerformJun 26, 2023
StifelDowngradedBuy → Hold$11.00 from $28.00Jun 26, 2023
William BlairDowngradedOutperform → Market PerformJun 26, 2023
StifelUpgradedHold → BuyJun 2, 2023
Cowen & Co.MaintainedMarket Perform$25.00 from $15.00Feb 28, 2023
Goldman SachsMaintainedSell$16.00 from $9.00Feb 23, 2023
Goldman SachsMaintainedSell$16.00 from $9.00Feb 21, 2023

Frequently asked questions

  • What is the latest analyst rating on KYNB?

    On Jul 7, 2026, Oppenheimer initiated coverage of Kyntra Bio at Outperform with a price target of $35.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.